[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delayed-gastric-emptying-following-procedure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delayed-gastric-emptying-following-procedure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100631841","acupuncture-for-postoperative-gastric-emptying-delay-100631841",false,"NCT07505927","Acupuncture for Postoperative Gastric Emptying Delay","Acupuncture for POstoperative Gastric Emptying dElay (APOGEE): A Multicenter Randomized Controlled Trial","APOGEE","Inclusion Criteria:\n\n1. Aged 18-80 years, regardless of sex.\n2. Patients who have undergone partial gastrectomy.\n3. Patients presenting with postoperative gastroparesis symptoms, confirmed by imaging or gastric emptying scintigraphy, and clinically diagnosed with gastroparesis.\n4. No severe cardiac, hepatic, renal, or coagulation dysfunction.\n5. No participation in other interventional clinical trials within the past month.\n6. Able to provide written informed consent and comply with the treatment and follow-up procedures.\n\nExclusion Criteria:\n\n1. Patients with severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or coagulation disorders.\n2. Patients who develop serious postoperative complications after partial gastrectomy, such as anastomotic leakage, gastrointestinal bleeding, or severe infections, or conditions that may affect the assessment of gastric motility, such as ascites or intestinal obstruction.\n3. Patients with a known allergy to acupuncture or with skin damage, infection, or severe scarring at the needle insertion sites that would prevent proper acupoint selection or needling.\n4. Patients with diagnosed psychiatric disorders, cognitive impairment, or those unable to cooperate with treatment procedures, symptom assessment, or follow-up.\n5. Patients who have used medications that may significantly affect gastric motility within the past week and cannot discontinue their use.\n6. Pregnant or breastfeeding women, or individuals with other special physiological conditions that may make them unsuitable for participation in acupuncture research.","ALL","18 Years","80 Years",{"count":21,"type":22},176,"ESTIMATED","INTERVENTIONAL",[25],"NA","This multicenter clinical trial, conducted at Qilu Hospital of Shandong University and collaborating institutions, prospectively assesses the efficacy and safety of acupuncture for postoperative delayed gastric emptying. Eligible participants will be prospectively enrolled and randomized into different groups per the study protocol. The primary endpoint is the reduction in the duration of delayed gastric emptying, while secondary endpoints include the complete resolution of cardinal gastroparetic symptoms, such as abdominal distension, nausea, and vomiting. All study procedures adhere to the ethical standards outlined in the approved protocol.",[28,29],"Gastroparesis Postoperative","Delayed Gastric Emptying Following Procedure",[31,32,33,34],"Gastroparesis","Acupuncture","Delayed Gastric Emptying","partial gastrectomy","RECRUITING","2026-04-15",{"date":38,"type":39},"2026-04-20","ACTUAL",{"date":41,"type":22},"2026-04-01",{"date":43,"type":22},"2028-06-01",{"name":45,"class":46},"Qilu Hospital of Shandong University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":47},"100493945","efficacy-and-safety-of-endoscopic-antral-myotomy-as-a-novel-weight-loss-procedure-100493945","NCT05711758","Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure","Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure: A Pilot Study","PSAM","Inclusion Criteria:\n\n* subjects must be 18-70 years of age\n* eligible for endoscopic and surgical weight loss procedures\n* body mass index (BMI) greater than 35 kg\u002Fm2\n* Individuals must be in excellent mental health\n* able to understand and sign informed consent\n* available to return for all routine follow-up study visits\n\nExclusion Criteria:\n\n* untreated H. pylori infection\n* gastroparesis\n* active smoking\n* an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment\n* previous pyloromyotomy or pyloroplasty\n* gastrointestinal obstruction\n* severe coagulopathy\n* esophageal or gastric varices and\u002For portal hypertensive gastropathy\n* pregnancy or puerperium\n* any inflammatory disease of the gastrointestinal tract (including but not limited to severe (LA Grade C or D) esophagitis, active gastric ulceration, active duodenal ulceration, or specific inflammation such as Crohn's disease)\n* malignant or premalignant gastric diseases (such as high grade dysplasia, gastric cancer, or GIST)\n* severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)\n* lactation\n* history of gastrointestinal surgery\n* any serious health condition unrelated to their weight that would increase the risk of endoscopy\n* chronic abdominal pain\n* active psychological issues preventing participation in a lifestyle modification program\n* a known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)\n* an inability to provide informed consent\n* use of any medication that may interfere with weight loss\n* use of any medication that may interfere with gastric emptying\n* any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study","70 Years",{"count":58,"type":22},30,"OBSERVATIONAL","Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.",[62,63,64,65,29],"Obesity","Obesity, Morbid","Obesity, Primary","Metabolic Disease",[67,68,69,70,71,72,73,74,75,76,77],"Pylorus Sparing Antral Myotomy (PSAM)","Gastric physiology","Gastric emptying","Pylorus-sparing antral myotomy","Myotomy","Endoscopic Sleeve Gastroplasty (ESG)","TransPyloric Shuttle (TPS)","Intragastric balloon (IGB)","Endoscopic bariatric and metabolic therapies (EBMT)","Gut Hormones","Gastric Emptying Breath Test","2026-02-26",{"date":80,"type":39},"2026-03-02",{"date":82,"type":39},"2023-09-22",{"date":84,"type":22},"2027-12",{"name":86,"class":46},"Christopher C. Thompson, MD, MSc",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":100,"conditions":101,"keywords":108,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100571535","phase-2-effectiveness-of-methods-for-pyloric-drainage-in-esophagectomy-botox-vs-pyloromyotomy-100571535","NCT06721520","Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy","Comparative Effectiveness of Intrapyloric Botulinum Toxin Injection Versus Pyloromyotomy for Pyloric Drainage During Esophagectomy: A Registry-Based, Pragmatic Randomized Noninferiority Trial","EMPTY","Inclusion Criteria:\n\n* 18 years of age or older\n* Undergoing elective esophagectomy (thoracoabdominal, Ivor-Lewis, McKeown)\n* Receiving a gastric conduit for alimentary reconstruction\n* Technically able to receive either intrapyloric Botox injection or pyloromyotomy as ultimately determined intraoperatively\n* Willing and able to provide informed consent\n* Willing and able to participate in long-term follow up including study visits and surveys\n\nExclusion Criteria:\n\n* Undergoing emergent esophagectomy (e.g., for esophageal perforation)\n* Patients with underlying neuromuscular disease as Botox would be contraindicated (amyotrophic lateral sclerosis, myasthenia gravis, muscular dystrophies, Lambert-Eaton syndrome)\n* Patients undergoing left thoracoabdominal without left cervical neck incision (i.e., Sweet esophagectomy) - excluded due to the extent of gastric resection\n* Pregnancy\n* Allergy or hypersensitivity to botulinum toxin\n* Cannot feasibly receive both pyloric interventions as determined intraoperatively (e.g., patients with central obesity undergoing thoracoabdominal esophagectomy makes for a technically difficult pyloromyotomy)",{"count":96,"type":22},170,[98,99],"PHASE2","PHASE3","The goal of this pragmatic, registry-based, randomized clinical trial is to find out if using botulinum toxin (Botox) to help drain the stomach during an esophagectomy works as well as a pyloromyotomy in patients undergoing elective esophagectomy for benign or malignant esophageal disease. Both methods are intended to prevent problems with food emptying too slowly from the stomach (delayed gastric emptying), which can cause discomfort after surgery. The main question it aims to answer is:\n\nIs intrapyloric Botox injection as a drainage procedure during esophagectomy non-inferior in preventing symptoms of delayed gastric emptying at 6 months postoperatively compared to pyloromyotomy?\n\nResearchers will compare intrapyloric Botox injection to pyloromyotomy to see if Botox is non-inferior to pyloromyotomy in easing symptoms of delayed gastric emptying.\n\nParticipants will:\n\nBe randomized to one of two treatment groups-either intrapyloric Botox injection or pyloromyotomy-during their esophagectomy.\n\nComplete surveys assessing digestive symptoms at standard postoperative follow-up intervals (3 months, 6 months, 1 year, and 2 years postoperatively).\n\nUndergo a standard gastric emptying study at 6 months after surgery.",[102,103,29,104,105,106,107],"Esophageal Cancer Surgery","Esophagectomy","Esophageal Diseases","Esophageal Achalasia","Pylorus Dysfunction","Esophageal Dysmotility",[103,109,110,111,112,113,114],"Delayed gastric emptying","Delayed conduit emptying","Botox","botulinum toxin","Pyloromyotomy","Pyloric drainage","2026-02-23",{"date":117,"type":39},"2026-02-25",{"date":119,"type":39},"2024-12-03",{"date":121,"type":22},"2028-05-31",{"name":123,"class":46},"The Cleveland Clinic"]